Both in Pharmaceuticals
Erasca vs Dianthus Therapeutics
Over the past year ERAS returned +545.5% and DNTH returned +158.5%; their daily moves had a correlation of 0.31.
ERAS +545.5% DNTH +158.5%Growth of $1, one year, split-adjusted
| Metric | ERAS | DNTH |
|---|---|---|
| Price | $14.91 | $85.81 |
| Market cap | $5.21B | $4.80B |
| Today | +1.84% | +3.76% |
| 1 month | +4.3% | +0.5% |
| 6 months | +36.8% | −5.1% |
| Year to date | +300.8% | +108.2% |
| 1 year | +526.5% | +152.2% |
| Revenue growth (YoY) | — | +294.3% |
| Gross margin | — | 100.0% |
| Net margin | — | −6598.6% |
| P/E (TTM) | — | — |
| Price / sales | — | 2,520.9× |
| Net cash | $268.7M | $886.8M |
| Dividend yield | — | — |
| Volatility (60d) | 59.7% | 38.9% |
| Short % of float | 14.5% | 18.4% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).